Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
This randomized phase III trial studies enzalutamide to see how well it works compared to
enzalutamide, abiraterone acetate, and prednisone in treating patients with
castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate
cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen
the amount of androgens made by the body.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.